ArticleAmerican journal of hematology2026

Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.

Simon Zhen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.